Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis

[1]  M. Sanz,et al.  Validation of a multivariable prediction model for post‐engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients , 2019, Mycoses.

[2]  P. Ljungman,et al.  European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. , 2018, The Journal of antimicrobial chemotherapy.

[3]  C. Chiu,et al.  Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study , 2018, PloS one.

[4]  M. Tormo,et al.  Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high‐risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real‐world comparison , 2018, Mycoses.

[5]  I. Raad,et al.  Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies. , 2017, International journal of antimicrobial agents.

[6]  L. Pagano,et al.  ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients , 2016, Haematologica.

[7]  V. Pavone,et al.  Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study) , 2015, Haematologica.

[8]  S. Krause,et al.  Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology , 2014, Annals of Hematology.

[9]  R. Foà,et al.  Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia. , 2014, Leukemia research.

[10]  C. Thompson,et al.  Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10‐year, single‐center experience , 2013, Transplant infectious disease : an official journal of the Transplantation Society.

[11]  L. Pagano,et al.  Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Tim Spelman,et al.  Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period , 2012, Haematologica.

[13]  C. Heussel,et al.  Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation , 2011, British journal of haematology.

[14]  F. Aversa,et al.  Etiology of febrile episodes in patients with acute myeloid leukemia: results from the Hema e-Chart Registry. , 2011, Archives of internal medicine.

[15]  A. Thiébaut,et al.  European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update , 2011, Bone Marrow Transplantation.

[16]  G. Egerer,et al.  Posaconazole prophylaxis in patients with acute myelogenous leukaemia – results from an observational study , 2011, Mycoses.

[17]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[18]  M. Hallek,et al.  Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. , 2010, The Journal of antimicrobial chemotherapy.

[19]  Giuseppe Leone,et al.  Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study , 2010, Haematologica.

[20]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  B. Thiers.  Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia , 2008 .

[22]  E. Estey,et al.  Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. , 2007, Blood.

[23]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[24]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .